Sage Therapeutics said Tuesday that an experimental pill designed to alleviate depression with a two-week course of therapy was successful in a large clinical trial involving patients with major depressive disorder.
The Sage drug, called zuranolone, demonstrated a statistically significant, anti-depressive benefit compared to a placebo. The positive results are a comeback win for Sage and its efforts to develop zuranolone for several different depressive disorders. The drug failed a similar study in December 2019.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
